Skip to NavigationSkip to content

Business Services

How COVID-19 is affecting diabetics and their access to insulin in America

Published on 15/12/20 at 11:45am

Diabetic patients face daily challenges of treatment access and treatment management, so 2020 has been a particularly challenging year. Conor Kavanagh analyses what specific factors are making the COVID-19 pandemic particularly deadly for diabetics.

PPAs - Ready to make a long-term commitment to zero carbon?

As an industry that consumes a large amount of energy, the pressure is on for the pharmaceutical sector to achieve its sustainability goals as the deadline for net zero edges closer.

For those looking to accelerate their renewable energy goals, Power Purchase Agreements (PPA) are a viable option and will help pharma businesses match their long-term horizons.

PPAs - Ready to make a long-term commitment to zero carbon?

Published date: 
15/12/2020
Summary: 
For those looking to accelerate their renewable energy goals, Power Purchase Agreements (PPA) are a viable option and will help pharma businesses match their long-term horizons.

As an industry that consumes a large amount of energy, the pressure is on for the pharmaceutical sector to achieve its sustainability goals as the deadline for net zero edges closer.

For those looking to accelerate their renewable energy goals, Power Purchase Agreements (PPA) are a viable option and will help pharma businesses match their long-term horizons.

Top Ten most popular articles on Pharmafile.com this week

With just around three weeks until the end of a long year, rapidly emerging news around the leading COVID-19 vaccine candidates continues to dominate. The Pfizer/BioNTech vaccine continues to lead the pack, having been approved for emergency use in the UK earlier this week. However, experts have warned that the therapy could cause an allergic reaction in some patients, while the candidate has even attracted the attention of hacker groups. 

Check out the week's ten most popular articles on Pharmafile.com now!

Pharmafile.com's weekly COVID-19 news round-up

Image credit: CDC

COVID-19 vaccine news continues to roll in and continues to be positive, with AstraZeneca now releasing Phase 3 data that proves its vaccine candidate is safe and effective. Vaccinations began this week in the UK with Pfizer and BioNTech's candidate after it secured emergency approval. However, despite all this good news, tech firm IBM says it has identified attempts by potentially state-sponsored hackers to compromise these new vaccination efforts. 

Top Ten most popular articles on Pharmafile.com this week

As the year winds to a close, excitement is rising around the efficacy and availability of COVID-19 vaccines around the world as global regulators race to review efficacy data without sacrificing robust analysis.

Our top ten most popular articles this week are unsurprisingly focused on many of the data and regulatory developments of these vaccine candidates.

10. EU fines Teva and Cephalon for keeping cheap sleep disorder medicine off the market

The Autumn 2020 edition of Pharmafile is available to read for free online now!

The Autumn 2020 edition of Pharmafile is available to read for free online now!

2020 has seen almost unprecedented disruption for life sciences at the hands of the COVID-19 pandemic. While the industry has somewhat acclimatised and the rollout of an effective vaccine could be around the corner, challenges remain.

Optimise your clinical trials with Avantor Clinical Services

Serious diseases like COVID-19 put increasing pressure on researchers to find breakthrough treatments faster. Along with accelerated timelines, biopharma and pharmaceutical companies also face operational challenges, like increased regulatory scrutiny, supply chain security and access to the mission-critical supplies that keep research moving forward.

Y-mAbs announces FDA approval of Danyelza for the treatment of Neuroblastoma

Photo by RadsWiki https://commons.wikimedia.org/wiki/File:Neuroblastoma_103.jpg

Y-mAbs Therapeutics has announced that the FDA has approved Danyelza in combination with granulocyte-macrophage colony-stimulating factor (“GM-CSF”), for the treatment of relapsed or refractory high-risk neuroblastoma of the bone or bone marrow in patients at least one uear old.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches